The spring season teaches us a lot about resiliency. Blooms from the healthiest plants not only survive the extremes of winter but thrive, year after year. The same is true for corporations. Despite more than two years of pandemic causing the most disruptive healthcare event in our lifetime, along with inflation at a 40-year high, Abbott continues to find fertile ground on which to grow. The company significantly beat Street estimates on the top and bottom lines. Here are the key numbers for the quarter: $1.73 in adjusted diluted earnings per share, which excludes specified items, reflecting 31.1% growth compared to the prior year.1 $11.9 billion in worldwide sales, growing 17.5% organic* (13.8% reported). $3.3 billion in global COVID-19 testing-related sales. Driving these results is Abbott's diversified business model — rooted in a strong base business with standout portfolios and rich pipelines — across multiple markets. Several of the company's businesses are performing at high levels, with double-digit organic sales growth in Medical Devices, Diagnostics and the branded generic medicines business. Abbott also continues strengthening its pipeline with new products and expanded reimbursement coverage, including FDA approval for its Aveir VR single-chamber leadless pacemaker, expanded indication for CardioMEMS — the company's remote monitoring system for heart failure — and expanded reimbursement in Japan for the FreeStyle Libre system. For full financials and reconciliation of non-GAAP measures, you can read Abbott's press release. For further information, take a look at some additional materials below: Abbott Chairman and CEO Robert Ford summarizes the company's first-quarter performance.